This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yeh, E. T.H. Search for Related Content PubMed PubMed Citation Articles by Yeh, E. T.H.

(Circulation. 2002;105:408.)
© 2002 American Heart Association, Inc.

Editorials

Ubiquitin, Proteasome, and Restenosis

A Brave New World for Cardiovascular Research

Edward T.H. Yeh, MD

From the Department of Cardiology, University of Texas M.D. Anderson Cancer Center, Department of Medicine and the Institute of Molecular Medicine for the Prevention of Human Diseases, University of Texas Houston Health Science Center; and Texas Heart Institute, St. Luke’s Episcopal Hospital, Houston, Tex.

Correspondence to Edward T.H. Yeh, MD, Dept of Cardiology, 1515 Holcombe Blvd, Box 449, University of Texas-M.D. Anderson Cancer Center, Houston, TX 77030-4095. E-mail etyeh@mdanderson.org

Key Words: Editorials • angioplasty • restenosis • proteins • enzymes

In the present issue of Circulation, Meiners and his colleagues¹ show that local application of a proteasome inhibitor resulted in significant inhibition of intimal hyperplasia in a balloon injury model in rat carotid artery. This report is of interest because it identifies a novel target for the treatment of restenosis and introduces a rapidly developing field in basic science to cardiovascular researchers. Proteasomes are large intracellular protein complexes that specialize in degrading cellular proteins that are either unneeded or damaged.^2–5 Inhibiting the activity of proteasome not only stops the ability of the cell to get rid of unwanted proteins, but also blocks most cellular processes critical for a cell’s survival. Inhibitors of proteasome activity have been used widely in basic research and more recently in anticancer clinical trials. It is not surprising that proteasome inhibitors can inhibit intimal hyperplasia because they generally have antiproliferative, antiinflammatory, and proapoptotic properties. In order to understand the inner workings of proteasome, one must become acquainted with a small protein called ubiquitin that serves as a molecular tag directing unneeded or damaged proteins to the proteasome for degradation.

See p 483

Ubiquitin, a 76 amino acid protein, is highly conserved in evolution with only a 3 amino acid difference between yeast and human homologues. Most of the known function of ubiquitin resides in its ability to covalently attach to other proteins through the formation of an isopeptide bond attaching the C-terminal Glycine residue of ubiquitin to a Lysine residue of the target protein.^2,4,5 A . . . [Full Text of this Article]

This article has been cited by other articles:

				X. Dong, J. Liu, H. Zheng, J. W. Glasford, W. Huang, Q. H. Chen, N. R. Harden, F. Li, A. M. Gerdes, and X. Wang In situ dynamically monitoring the proteolytic function of the ubiquitin-proteasome system in cultured cardiac myocytes Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1417 - H1425. [Abstract] [Full Text] [PDF]